Biopharmaceutics deal

BPII acquired a 50 percent interest in KKKI-538, an anti-HIV oligodeoxynucleotide compound, from the Central Research Institute for Chemistry of the Hungarian Academy of Sciences (CRIC). BPII paid $300,000 up front and will pay $4.3 million over the next two years. ...